A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors. by Loriot, Axelle et al.
Available at:
http://hdl.handle.net/2078.1/152152
[Downloaded 2019/04/19 at 10:14:30 ]
"A novel cancer-germline transcript carrying pro-
metastatic miR-105 and TET-targeting miR-767
induced by DNA hypomethylation in tumors."
Loriot, Axelle ; Van Tongelen, Aurélie ; Blanco, Jordi ; Klaessens, Simon ;
Cannuyer, Julie ; van Baren, Nicolas ; Decottignies, Anabelle ; De Smet, Charles
Abstract
Genome hypomethylation is a common epigenetic alteration in human tumors,
where it often leads to aberrant activation of a group of germline-specific genes,
commonly referred to as "cancer-germline" genes. The cellular functions and
tumor promoting potential of these genes remain, however, largely uncertain.
Here, we report identification of a novel cancer-germline transcript (CT-
GABRA3) displaying DNA hypomethylation-dependent activation in various
tumors, including melanoma and lung carcinoma. Importantly, CT-GABRA3
harbors a microRNA (miR-105), which has recently been identified as a promoter
of cancer metastasis by its ability to weaken vascular endothelial barriers
following exosomal secretion. CT-GABRA3 also carries a microRNA (miR-767)
with predicted target sites in TET1 and TET3, two members of the ten-eleven-
translocation family of tumor suppressor genes, which are involved in the
conversion of 5-methylcytosines to 5-hydroxymethylcytosines (5hmC) in DNA.
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Introduction
DNA methylation in mammalian genomes, which occurs 
mostly at cytosines within CpG dinucleotides, is a potent mecha-
nism of gene repression, and contributes thereby to the estab-
lishment and maintenance of cell-type specific gene expression 
programs.1 Genome methylation patterns often undergo pro-
found alterations in human tumors.2 Both gains (hypermeth-
ylation) and losses (hypomethylation) of CpG methylation are 
observed. DNA hypermethylation often affects CpG-rich pro-
moters of tumor suppressor genes, leading to their irreversible 
silencing. DNA hypomethylation, on the other hand, has been 
associated with aberrant activation of a limited group of protein-
coding genes, most of which have their transcription normally 
restricted to the germ line.3,4 Genes in this group, commonly 
referred to as ‘cancer-germline’ (CG) genes, are indeed character-
ized by their strict reliance on DNA methylation for repression 
in normal somatic tissues.5,6 Intriguingly, most CG genes map on 
the X chromosome.4 It is still unclear, however, if activation of 
CG genes, which appear to exert a variety of cellular functions, 
plays a major oncogenic role in hypomethylated tumor cells.3
In the present study, we searched to determine if DNA 
hypomethylation in tumors also induces aberrant expression of 
miRNA-producing cancer-germline transcripts. There is indeed 
mounting evidence that dysregulated expression of miRNAs, 
which exert important regulatory functions through their abil-
ity to induce post-transcriptional inhibition of target mRNAs, 
contributes to cancer development.7,8
Results
Aberrant activation of GABRA3 and hosted miR-105 and 
miR-767 in tumors
As an initial step in our search for CG-type miRNAs, we per-
formed an in silico screening in miRNA databases (microRNA.
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Genome hypomethylation is a common epigenetic alteration in human tumors, where it often leads to aberrant 
activation of a group of germline-specific genes, commonly referred to as “cancer-germline” genes. the cellular func-
tions and tumor promoting potential of these genes remain, however, largely uncertain. here, we report identification 
of a novel cancer-germline transcript (CT-GABRA3) displaying DNA hypomethylation-dependent activation in various 
tumors, including melanoma and lung carcinoma. importantly, CT-GABRA3 harbors a microrNA (mir-105), which has 
recently been identified as a promoter of cancer metastasis by its ability to weaken vascular endothelial barriers fol-
lowing exosomal secretion. CT-GABRA3 also carries a microrNA (mir-767) with predicted target sites in TET1 and TET3, 
two members of the ten-eleven-translocation family of tumor suppressor genes, which are involved in the conversion 
of 5-methylcytosines to 5-hydroxymethylcytosines (5hmc) in DNA. Decreased tet activity is a hallmark of cancer; here, 
we provide evidence that aberrant activation of mir-767 contributes to this phenomenon. We demonstrate that mir-767 
represses TET1/3 mrNA and protein expression and regulates genomic 5hmc levels. Additionally, we show that high CT-
GABRA3 transcription correlates with reduced TET1 mrNA levels in vivo in lung tumors. together, our study identified a 
cancer-germline gene that produces microrNAs with oncogenic potential. Moreover, our data indicate that DNA hypo-
methylation in tumors can contribute to reduced 5hmc levels via activation of a TET-targeting microrNA.
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org and miRBase.org), using as filtering criteria two character-
istics of CG genes: predominant expression in testis and local-
ization on the X chromosome. This led to the selection of 21 
X-linked miRNAs with predicted expression in testis and in no 
more than one normal somatic tissue. Among these, we noticed 
a pair of miRNAs (miR-105 and miR-767), deriving from the 
first intron of GABRA3, a gene encoding a receptor subunit for 
the γ-aminobutyric-acid neurotransmitter. Our interest for these 
miRNAs was prompted by the fact that, although GABRA3 
expression is normally restricted to brain and testis, aberrant 
transcription of the gene was reported in several tumor types, 
and was identified as a significant predictor of poor survival in 
lung cancer patients.9-12 Moreover, GABRA3 is located within a 
region of the X chromosome (Xq28) that harbors many known 
CG genes. RT-qPCR experiments with primers located in exons 
5 and 6 of GABRA3 confirmed specific expression of this gene in 
brain and testis, and revealed its activation in melanoma cell lines 
and tissues (Fig. 1A,B). In parallel, RT-qPCR directed toward 
miR-105 and miR-767 indicated that expression of these miR-
NAs strictly mirrors that of their host gene (Fig. 1B). Additional 
analyses in larger sets of tumor samples detected GABRA3 tran-
scripts in 65% of melanoma tissues and in 40% of lung tumors 
(Fig. 1C).
Tumors express a cancer-testis variant of GABRA3: 
CT-GABRA3
To further characterize the composition of GABRA3 tran-
scripts in tumor cells, RT-PCR experiments with primers located 
in different exons were performed. Surprisingly, RT-PCR with 
primers located in exon 1 and 2 of GABRA3 amplified the 
transcript in brain and testis, but failed to detect it in most 
tumor cells (Fig. 1A,D). This suggested the existence of an 
alternative form of GABRA3 transcript in tumors. In order to 
identify this transcript variant, we performed 5′ RACE experi-
ments in GABRA3-expressing melanoma cell lines. This led 
to the identification of an alternative transcription start site 
located 247-kb upstream of the reference GABRA3 start site. 
We isolated several novel transcript variants originating from 
this start site, which contained alternatively spliced exons in the 
5′ part followed by all exons but exon 1 of GABRA3 (Fig. 1A, 
and Fig. S1). GABRA3 transcripts originating from this alter-
native start site were named CT-GABRA3 (Cancer-Testis), as 
opposed to the reference GABRA3 transcript, which, for sake 
of clarity, we re-named BT-GABRA3 (Brain-Testis). Unlike 
BT-GABRA3, CT-GABRA3 displayed a typical cancer-germ-
line pattern of expression, as it was expressed in testis but not 
in brain, and was commonly activated in tumor cells (Fig. 1D). 
CT-GABRA3 transcripts comprise several short upstream open 
reading frames, which were found to inhibit translation of the 
GABRA3 protein (Fig. S2). Interestingly, the transcription 
start site of CT-GABRA3 is located nearby that of a known CG 
gene, MAGEA3, oriented in the opposite direction (Fig. 1A). 
Both genes appear therefore to share a bidirectional promoter, 
as supported by their frequent co-activation in melanoma and 
lung tumor samples (Fig. S3).
Figure 1. tumors show aberrant expression of a testis-specific transcript variant of GABRA3, and of the mirNAs it harbors. (A) schematic representa-
tion of the human GABRA3 locus, with broken arrows indicating transcription start sites. the exon/intron structure of the referenced GABRA3 transcript 
(re-named BT-GABRA3) and of the newly characterized transcript variant (CT-GABRA3) is shown below, with arrowheads indicating the orientation and 
location of pcr primers used in subsequent expression analyses. (B) expression analysis of GABRA3, mir-105 and mir-767 in normal human tissues and 
melanocytes, as well as in melanoma cell lines (1, Mi13443-MeL; 2, sK-MeL-23; 3, BB74-MeL; 4, MZ2-MeL; 5, LB2667-MeL; 6, Mi665/2-MeL) and tissue sam-
ples (Table S1). primers a and b amplify both BT-GABRA3 and CT-GABRA3 transcripts. Normalized mrNA (ratio to ACTB) and mirNA (ratio to SNORD44) 
levels are expressed relative to the brain sample taken as 100% reference. (C) rt-qpcr analysis of GABRA3 with primers a and b, in a larger series of mela-
noma samples (n = 25), and in non-small-cell lung carcinoma (NscLc) tissue samples (n = 27). see table S1 for sample descriptions. GABRA3 mrNA levels 
are expressed relative to the MZ2-MeL melanoma cell line taken as 100% reference. (D) Gel analysis of rt-pcr experiments with primers recognizing 
either both GABRA3 transcript variants (primers a and b), only BT-GABRA3 transcripts (primers c and d), or only CT-GABRA3 transcripts (primers e and d).
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CT-GABRA3 activation in tumors is dependent on DNA 
demethylation
We next investigated whether activation of CT-GABRA3 and 
its hosted miRNAs in tumors is linked to DNA hypomethyl-
ation. Sensitivity of CT-GABRA3 expression to DNA demethyl-
ation-dependent activation was demonstrated in an experiment 
showing induction of this transcript, but not of BT-GABRA3, 
following treatment of non-expressing cells with the DNA meth-
ylation inhibitor, 5-aza-2’-deoxycytidine (5-azadC; Figure 2A). 
Not surprisingly, the DNA methylation inhibitor also induced 
expression of miR-105 and miR-767 (Fig. 2B). Moreover, 
sodium bisulfite sequencing revealed that CT-GABRA3 expres-
sion in testis and tumor cells is associated with extensive pro-
moter demethylation (Fig. 2C). Consistent with a primary role 
of genome demethylation in the activation of CT-GABRA3 in 
tumor cells, we observed a significant trend of co-activation of 
this gene with other DNA methylation-sensitive CG genes in 
melanoma cell cultures (Fig. S4). Together, our results indicate 
that mir-105 and mir-767 are carried by two transcript variants of 
GABRA3: BT-GABRA3, which is transcribed in brain and testis; 
and CT-GABRA3, which normally displays specific transcription 
in testis, but also becomes activated as a result of DNA demeth-
ylation in tumor cells. We conclude that DNA hypomethylation 
in tumors is associated with aberrant activation of miR-105 and 
miR-767 expression.
TET1 and TET3 are targets of miR-767
During the course of our research project, a study was pub-
lished showing that miR-105 is expressed in metastatic breast 
cancer cells, and acts as a crucial promoter of cancer metastasis.13 
The study revealed indeed that miR-105 undergoes exosome-
mediated secretion, and destroys vascular barriers by inhibiting 
expression of the tight junction protein ZO-1 in endothelial cells. 
Our data indicate that miR-105 is expressed in other tumor types 
as well, and reveal that DNA hypomethylation accounts for its 
tumor-specific activation. In order to get more insight into the 
function of miR-767 and its potential contribution to tumor 
development, we decided to search relevant mRNA targets of this 
miRNA with the help of prediction algorithms. We focused our 
attention on two potential targets of miR-767, TET1 and TET3, 
because TET genes were recently shown to exert tumor-suppres-
sive functions.14 The TET family of genes (TET1, TET2, and 
TET3) encode dioxygenases that are recruited to specific regions 
of the genome, where they contribute to processes of localized 
DNA demethylation by converting 5-methylcytosines (5mC) to 
5-hydroxymethylcytosines (5hmC).15,16 TET activities are often 
downregulated in a wide variety of cancers, leading to marked 
reduction in genomic 5hmC levels.17-19 In a significant propor-
tion of hematopoietic malignancies, this has been associated with 
mutations in TET2.17 In most solid tumors, however, the origin 
of reduced TET activities has remained unclear.
Effective targeting of TET1 and TET3 genes by miR-767 
was confirmed by transfection experiments showing that syn-
thetic miR-767 molecules, but not control miRNA molecules, 
induce downregulation of luciferase reporter genes linked to the 
3′-UTR of either TET1 or TET3 (Fig. 3A,B). Importantly, we 
also demonstrated that expressing tumor cells contain sufficient 
amounts of endogenous miR-767 to inhibit expression of the 
TET1 3′-UTR luciferase reporter gene, and we confirmed that 
this inhibition involves a direct interaction, by showing impaired 
inhibition of a reporter that carries a mutant version of the TET1 
3′-UTR lacking miR-767 target sequences (Fig. 3C, and Fig. S5). 
We then assessed whether miR-767 can regulate endogenous 
TET1 and TET3 mRNA levels. In HEK293T human embryonic 
kidney cells and in TERA-1 human embryonal carcinoma cells, 
which both lack constitutive expression of miR-767, transfection 
of synthetic miR-767 molecules resulted in reduced TET1 and 
TET3 mRNA levels, although this reduction was not significant 
for TET3 in TERA-1 cells (Fig. 3D). Conversely, inhibition of 
Figure 2. expression of CT-GABRA3, mir-105 and mir-767 is induced by DNA demethylation. (A) three GABRA3-negative melanoma cell lines (-MeL), and 
an immortalized fibroblast cell line (BJhtert) were cultured in the presence (+) or in the absence (-) of 5-azadc. expression of CT-GABRA3, BT-GABRA3 
and ACTB (control) was analyzed by rt-pcr. (B) expression of mir-105 and mir-767 was analyzed by rt-qpcr in similarly treated cell lines, including 
the terA-1 embryonal carcinoma cell line. relative mirNA levels are expressed as ratio to SNORD44 (x 104). (C) Bisulfite sequencing of the MAGEA3/
CT-GABRA3 promoter region. sequences could not be distinguished from those deriving from the MAGEA6 promoter region, as both loci show 100% 
sequence identity. Vertical bars indicate location of cpG sites with positions relative to the CT-GABRA3 start site. open and filled squares represent 
unmethylated and methylated cpG sites, respectively, and each row represents a single clone. CT-GABRA3 expression status (+) or (-) in samples is indi-
cated (positive samples also express MAGEA3 and MAGEA6). highly methylated sequences in testis likely derive from somatic cells in the tissue sample.
©
20
14
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
1166 epigenetics Volume 9 issue 8
miR-767 by antisense oligonucleotides in expressing tumor cell 
lines resulted in a significant elevation in TET1 mRNA levels 
(Fig. 3E). For TET3, we observed a less constant effect of the 
inhibitor, as only one out of the four treated cell lines showed an 
increased level of TET3 mRNA (Fig. 3E). We also confirmed 
the ability of miR-767 to inhibit TET1 and TET3 expression at 
the protein level, by showing decreased amounts of these proteins 
in HEK293T cells upon transfection with synthetic miR-767 
molecules (Fig. 3F). Finally, we assessed whether miR-767 can 
regulate 5hmC levels. Slot blot assays with anti-5hmC antibodies 
showed that the transfection of synthetic miR-767 molecules in 
both TERA-1 and HEK293T cells indeed resulted in a signifi-
cant reduction of global 5hmC levels (Fig. 3G). Taken together, 
these data indicate that miR-767 can function as a regulator of 
Figure 3. mir-767 controls TET1 and TET3 expression levels and regulates cellular 5hmc levels. (A) red triangles indicate the location of mir-767 seed 
sequences (7-mer and 8-mer) in TET1 and TET3 3′-Utrs. (B) heK293t cells were co-transfected with a luciferase reporter linked to the 3′-Utr of either 
TET1 or TET3, and with the indicated mirNAs (mir-ctrl and mir-137 served as a negative control). Normalized luciferase activities, which were measured 
24h after transfection, are expressed relative to mock cells (no mirNA transfected), and represent means ± seM (n = 3). *** P < 0.001 for comparison to 
mock cells (Bonferroni’s multiple comparison test). (C) heK293 cells (mir-767 negative) and Mi13443-MeL cells (mir-767 positive) were stably transfected 
with a luciferase reporter vector carrying either the wild-type (wt) 3′-Utr of TET1 or a mutant version of the 3′-Utr (mut4), lacking the four mir-767 
target sequences. relative luciferase units represent mean ± seM (n = 3). *** P < 0.001. (D) TET1 and TET3 mrNA levels were evaluated by rt-qpcr three 
days after transfection of mir-105 (serving as negative control) or mir-767. Normalized mrNA levels (ratio to ACTB) are expressed relative to mock cells 
(no mirNA transfected). Values represent mean ± seM (n ≥ 3). * P < 0.05, for comparison to mock cells (friedman test with Dunn’s multiple comparison 
test). (E) mir-767-expressing melanoma cell lines (-MeL) and non-small cell lung carcinoma cell line (GLcp1) were transfected with a LNA inhibitor of 
mir-767 (mir767-inh) or an irrelevant control LNA inhibitor (ctrl-inh). TET1 and TET3 mrNA expression levels were assessed by rt-qpcr. Values represent 
mean ± seM (n = 3). * P < 0.05 (Wilcoxon signed rank tests). (F) heK293t cells transfected with the indicated mirNA or sirNA were subjected to western 
blot analysis for tet1 and tet3 proteins (p80-Ku was assessed to verify equal loading). (G) Genomic 5hmc levels were evaluated by slot blot analysis at 
day 3 after transfection with the indicated mirNA. Blots were stained with methylene blue to control for loading. representative blots are shown out 
of three to five repeats. Quantification of slot blot data was performed. Normalized 5hmc levels are expressed relative to mock-transfected cells, and 
represent mean ± seM * P < 0.05 (friedman test with Dunn’s multiple comparison test). (H) Analysis of microarray data derived from the tcGA collection 
of lung squamous cell carcinomas (n = 120) revealed significant downregulation of TET1 (but not TET3) in tumor cells that show upregulation of mir-
767-harboring GABRA3 transcripts. positive correlation between GABRA3 and MAGEA3 activation confirmed the validity of the test. red bars indicate 
mean mrNA levels. P values were determined by unpaired t tests.
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cellular 5hmC levels via targeting of TET genes. In our experi-
ments, miR-767 exhibited a preferential effect on TET1.
We next searched to determine if miR-767 expression is 
indeed correlated with reduced expression of TET genes in vivo 
in tumor tissues. To this end, we analyzed publicly available 
microarray data, and searched if we could find a negative correla-
tion between the expression of TET1/3 genes and the presence of 
miR-767-harboring GABRA3 transcripts (probes on microarrays 
detect both CT- and BT-GABRA3 transcripts). miRNAs usually 
induce only limited decrease in the level of their target mRNAs. 
We nevertheless observed a significant correlation between 
increased GABRA3 expression and reduced TET1 mRNA lev-
els in lung carcinoma tissues (Fig. 3H), a tumor type where 
GABRA3 upregulation was identified as a predictor of poor sur-
vival. TET3 did not seem to be affected, suggesting that TET1 is 
a preferred target of miR-767 in lung carcinoma.
Discussion
One common target of DNA hypomethylation in tumors is 
the group of CG genes, which normally displays specific expres-
sion in germline cells. As a consequence, aberrant transcrip-
tion of these genes is observed in a large variety of tumor types. 
Evidence that CG genes exert tumor-promoting roles has however 
remained scarce. Our identification of CT-GABRA3 provides the 
first example, to the best of our knowledge, of a CG gene that 
harbors miRNAs with oncogenic potential. One of these miR-
NAs, miR-105, was shown very recently to be expressed in breast 
cancer cells, and to be released in the extracellular environment 
via exosome secretion.13 Secreted miR-105 targets tight junction 
protein ZO-1 in endothelial cells, thereby facilitating cancer cell 
migration to distant locations. Our study establishes therefore a 
connection between DNA hypomethylation, CG gene activation, 
and cancer metastasis.
CT-GABRA3 also produces miR-767, and we demonstrate 
that this miRNA targets genes of the TET family. TET genes 
encode epigenetic regulators, which were found to exert tumor 
suppressive functions, notably through their impact on cell 
differentiation and invasion.18,20,21 A recent study revealed the 
existence of an extensive network of TET-targeting miRNAs.22 
Among these, several miRNAs, including miR-29b and miR-22, 
were shown to contribute to the development of hematopoietic 
and breast cancers, in a manner that depended on their effect on 
TET gene expression.22,23 This demonstrates that TET-targeting 
miRNAs can have a critical impact on tumor cell functions, 
even though their effects on TET expression levels are generally 
very subtle.22,24 In this regard, it is worth noting that monoal-
lelic mutation of Tet2 was sufficient to promote myeloprolifera-
tive disorders in mice models, suggesting physiologically relevant 
gene dosage effects.25,26 The specific contribution of miR-767 to 
the regulation of TET activities in tumor cells will likely vary 
according to the level of expression of other TET-targeting miR-
NAs. Compared with these miRNAs, miR-767 displays a much 
more contrasted pattern of expression, as it is completely silenced 
in all tissues, except brain and testis, and becomes activated in 
a wide variety of tumors. We anticipate therefore that miR-767 
can exert a critical tumor-promoting function in several tumor 
types. Interestingly, a recent study, which conducted a systematic 
screening for miRNAs involved in cell migration, identified miR-
767 as a potential candidate.27 This finding supports a possible 
pro-metastatic role of miR-767, when expressed in tumor cells.
Intriguingly, our results concerning miR-767 reveal the exis-
tence of an unexpected link between DNA methylation and TET 
genes, whereby genome demethylation can lead to inhibition of 
TET activities via activation of a TET-targeting miRNA. DNA-
hypomethylation-mediated activation of miR-767 in tumors 
is therefore expected to cause subsequent epigenetic remodel-
ing events. For instance, because TET proteins are required to 
maintain select genomic sequences in a DNA methylation-free 
status,28 their downregulation by miR-767 may facilitate DNA 
hypermethylation at specific gene promoters. This raises the 
interesting possibility of a link between DNA hypomethylation 
and DNA hypermethylation in tumor cells.
In a more physiological context, we hypothesize that miR-767 
may contribute to an epigenetic regulatory circuit in developing 
germ line cells, where transient processes of DNA demethylation 
involving TET enzymes are taking place.29,30 One possibility is 
that miR-767 becomes activated upon completion of these DNA 
demethylation processes, and then inhibits TET activities in 
order to allow subsequent re-methylation of specific DNA sites. 
The timeframe of activation of CG genes in developing germ-
line cells is compatible with this proposed role of miR-767.31-33 
Experimental validation of this hypothesis can be envisaged in 
the mouse, where miR-767 location in the X-linked Gabra3 gene, 
and target sites in the 3′-UTR of Tet genes, are conserved.
The other site of constitutive miR-767 expression is brain, 
where 5hmC levels are generally high.34 Interestingly, TET1 was 
found to be significantly downregulated by neuronal activity,35 
suggesting the existence of intricate regulatory mechanisms, in 
which miR-767 might be implicated. This may have important 
implications in memory formation and extinction.35,36
Material and Methods
Cell lines and tumor tissue samples
All human melanoma cell lines, which derive from cutane-
ous melanoma metastases, and the GLCP1 cell line, which 
derives from a human NSCLC, were obtained from the Brussels 
Branch of the Ludwig Institute for Cancer Research, and were 
cultured as previously described.5 TERA-1 human embryonal 
carcinoma cells were kindly provided by W. Schultz (Heinrich 
Heine University, Germany), and their culture conditions are 
described elsewhere.37 HEK293T cells, which were purchased 
from Thermo Fisher, HEK293 cells, which were kindly provided 
by B. Lauwerys (Université catholique de Louvain, Belgium), and 
BJhTERT cells, which were a gift from F. d’Adda di Fagagna 
(IFOM foundation, Italy), were maintained in high glucose 
DMEM (Life Technologies), supplemented with GlutaMAX™ 
(Life Technologies), 1 x non-essential amino acids (Life 
Technologies), 1 x Penicillin/Streptavidin (Life Technologies), 
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and 10% fetal bovine serum (Hyclone). Early passage human 
normal epidermal melanocytes (HNEM) were received from 
E. De Plaen (Ludwig Institute for Cancer Research, Belgium), 
and were cultured in Ham’s F10 medium (Life Sciences) sup-
plemented with 6 mM Hepes, 1 x MelanoMax supplement 
(Gentaur), and 10% fetal bovine serum. A description of human 
melanoma and NSCLC tissue samples is provided in the table 
S1. They were obtained from the Brussels Branch of the Ludwig 
Institute for Cancer Research
RT-PCR and RT-qPCR analyses
Total RNA samples were purchased from Ambion Life 
Technologies, or prepared from cell lines and surgical specimens 
(obtained from the Ludwig Institute for Cancer Research, Belgium) 
using either TriPure Isolation Reagent (Roche Diagnostics GmbH) 
or the guanidinium-isothiocyanate/cesium chloride procedure.38 
Reverse transcription was performed on 2 μg of total RNA using 
either PrimeScript Reverse transcriptase (Takara) and random hex-
amers primers, or M-MLV Reverse transcriptase (Invitrogen) and 
dT18 primers. The transcripts were amplified from 1/40 of the 
reverse transcription reaction. Conventional PCRs were performed 
using the DreamTaq polymerase (Thermo Fisher Scientific), in a 
final reaction volume of 25 μl. Quantitative RT-PCR amplifica-
tions were performed using the qPCR Core kit (Eurogentec). All 
qPCRs where SybrGreen assays, except for the GABRA3 qPCR, 
which was a Taqman assay. Primers and probe sequences are listed 
in the table S2.
For miRNA RT-qPCR analyses, 20ng of total RNA was used 
for the RT with the Universal cDNA Synthesis Kit II (Exiqon). 
miRNAs were amplified from 1/320 of the reverse transcrip-
tion reaction, using LNA primers specific for hsa-mir-767–5p 
(#204238, Exiqon) and hsa-mir-105–5p (#204389, Exiqon). 
LNA primers specific for SNORD44 (#203902, Exiqon) were 
used for normalization. qPCR was performed using the qPCR 
Core Kit (Eurogentec).
Rapid amplification of 5′ cDNA ends (5′-RACE)
Two protocols of 5′-RACE were applied, which were based on 
the use of either ThermoScript Reverse Transcriptase (Fig. S1B) 
or PrimeScript Reverse Transcriptase (Fig. S1C).
For Thermoscript 5′-RACE: reverse transcription was per-
formed on 3 μg of total RNA using ThermoScript Reverse 
Transcriptase (Invitrogen), according to manufacturer’s instruc-
tions. Ten pmoles of GABRA3-specific primer (GABRA3b) and 
10 pmoles of SMART IV oligo from the SMART™ cDNA 
Library Construction Kit (Clontech) were used for the reaction. 
The reaction was incubated during 1 h at 58 °C, and stopped 
by heating 5 min at 80 °C. The reaction was subsequently incu-
bated for 20 min at 37 °C in the presence of 1 unit of RNaseH 
(Invitrogen). The 5′-RACE products were amplified from 1/20 
of the reverse transcription reaction, with 0.625 units of TaKaRa 
Taq DNA polymerase (Takara). Three rounds of nested PCR, 
with primers indicated in Figure S1 (see sequence in accompany-
ing table), were applied. PCR products were run on an agarose 
gel, and purified with the QIAquick Gel Extraction Kit (Qiagen) 
before sequencing.
For PrimeScript 5′-RACE: Reverse transcription was per-
formed on 1 μg of total RNA using PrimeScript Reverse 
Transcriptase (Takara), according to manufacturer’s instructions. 
Ten pmoles of random hexamers and 10 pmoles of SMART IV 
oligo were used in the reaction. The reaction was incubated for 1 
h at 42 °C, and stopped by heating 7 min at 72 °C. Subsequent 
steps were as described here above.
DNA fragments generated by 5′-RACE and RT-PCR analy-
ses were sequenced with the BigDye® Terminotor V3.1 Cycle 
Sequencing kit (Life technologies), according to the manufac-
turer’s recommendation. Sequencing reactions were purified 
with the BigDye® XTerminator kit (Life technologies) and were 
run on an ABI 3130xL Genetic Analyzer (Life technologies). 
Sequence of the full-length CT-GABRA3 transcript has been 
submitted to GenBank under the accession number KJ620007.
5-Aza-2′-deoxycytidine treatment
Cells grown to 60–70% confluence were exposed to a sin-
gle dose of 2 μM 5-aza-2′-deoxycytidine (Sigma-Aldrich), and 
maintained in culture during 6 d (a period of time corresponding 
to at least 3 population doublings) before RNA extraction.
Sodium bisulfite genomic sequencing
Sodium bisulfite genomic sequencing of the MAGEA3/
CT-GABRA3 promoter region was performed as described previ-
ously.39 Primer used for nested PCR amplification of bisulfite treated 
DNA were respectively TYGATTTTTA TTTAGGTAGA ATTT 
and TAAAATAATA ACRACCCAAC CTAA (1st PCR) and 
ATTTAGGTAGA ATTTAGTTTT AT and CCCTACRAAA 
TAACCCAAA (2nd PCR). These primers sets also amplify the 
MAGEA6 promoter region, which shows 100% sequence identity.
Construction of luciferase reporter vectors and luciferase 
assays
TET1 and TET3 3′-UTRs were amplified by PCR using the 
high fidelity PrimeStar HS DNA polymerase (Takara), with 
primers carrying a 5′ overhang containing a restriction site for 
either XhoI (sense primer) or Not1 (antisense primer) (see table 
S2). PCR fragments were cloned between the corresponding 
restriction sites into the psiCHECK™-2 vector (Promega). 
Vector inserts were sequenced to verify the presence of error-free 
miR-767 target sequences.
The luciferase reporter vector containing the mutant version 
of TET1 3′-UTR was generated by site directed mutagenesis of 
the wild-type vector, using the QuickChange multi site-directed 
mutagenesis kit (Stratagene), and according to the manufactur-
er’s instructions. Mutagenic primers (TET1-mut1 to -mut4, see 
Table S1) were designed using the QuickChange primer design 
program (www.agilent.com/genomics/qcpd).
In co-transfection of miRNA and luciferase reporter experi-
ments, 2.x104 HEK293T cells were seeded in each well of a 
96-well plate. After 24h, cells in each well were transfected using 
the Lipofectamine 2000 reagent (Invitrogen, Life Sciences), with 
0.05 ng of the luciferase reporter vector and mirVana miRNA 
Mimics (Ambion, ThermoScientific) at a final concentration of 
10 nM (Fig. 3B or 3 nM (Fig. S3B). Luciferase activities were mea-
sured 24h after transfection by using the Dual-Glo® Luciferase 
Assay System (Promega) and a Glomax® 96 Microplate lumi-
nometer (Promega).
In the experiments of stable transfection of luciferase reporters 
in HEK293 cells, cells were seeded at ~40% confluency in 75 
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cm2 flasks, and were transfected 24h later, using Lipofectamine 
2000, with 20 µg of the reporter vector, 10 µg of genomic DNA, 
and 1 µg of pCDNA3 (carrying a neomycin resistance gene; 
Invitrogen). Transfectants were selected in 0.8 mg/ml G418 
Geneticin® (Invitrogen, Life Sciences), and were harvested after 
19 d of selection for analysis of luciferase activities. For Mi13443-
MEL cells, cells were seeded at ~50% confluency in 75 cm2 flasks, 
and were transfected 24h later, using the Genius DNA transfec-
tion reagent (Westburg) according the manufacturer’s instruc-
tions, with 10 µg of the reporter vector, and 1 µg of pCDNA3. 
Transfectants were selected in 0.8 mg/ml G418 Geneticin®, and 
were harvested at different time points (day 14, 17 and 22) for 
analysis of luciferase activities.
Transfection of synthetic miRNAs and miRNA inhibitors
For analysis of the effect of miRNA transfection on endog-
enous TET mRNA and protein levels, and on 5hmC levels, 
synthetic mirVana miRNA Mimics were transfected at a final 
concentration of 50 nM using the Lipofectamine 2000 reagent 
(Invitrogen, Life Sciences) in HEK293T cells; and at a final con-
centration of 50 nM using the Lipofectin reagent (Invitrogen, 
Life Sciences) in TERA-1 cells. In both cases, the manufacturer’s 
instructions were applied.
For analysis of miRNA inhibitors on TET expression levels 
in tumor cells, 5′-fluorescein-labeled miRCURY LNA™ Power 
microRNA inhibitors (Exiqon) were transfected at a final con-
centration of 100 nM, using the ExGen 500 transfection reagent 
(Thermo Scientific) for Mi13443-MEL cells, the Genius DNA 
transfection reagent for LB373-MEL cells, and the Lipofectamine 
2000 transfection reagent for LB2201-MEL and GLCP1 cells. In 
all cases, the manufacturer’s instructions were applied, and visual 
analysis under a fluorescent microscope revealed nearly 100% 
transfection efficiencies. Cells were harvested at day one after 
transfection for TET1/3 gene expression analysis.
Western blotting
Whole cell lysates were obtained by harvesting cells in 1 x 
Laemmli buffer complemented with the cOmplete Mini protease 
inhibitor cocktail (Roche), PhosphoStop phosphatase inhibitor 
cocktail (Roche), and 1 mM of phenylmethanesulfonyl fluoride 
(Sigma-Aldrich). Whole cell lysates were denatured for 10 min 
at 99 °C, sonicated with a Bioruptor sonicator (Diagenode), and 
reheated for 5 min at 99 °C before loading and electrophoresis in 
a 4–15% acrylamide Mini-Protean® TGX gel (Biorad). Proteins 
were thereafter submitted to an overnight electrotransfer on a 
polyvinydilene difluoride Immobilon®-P transfer membrane 
(Millipore) at 4 °C. The membrane was thereafter saturated in 
a PBS solution containing 4% non-fat milk and 0.05% Tween 
20 during 1h at room temperature. Incubation with the primary 
antibodies was performed in the same solution either overnight at 
4 °C for TET1 and TET3, or during 1h at room temperature for 
p80-Ku. Primary antibodies were: anti-TET1 rabbit polyclonal 
antibody (1:5000, GT1462, Genetex), anti-TET3 rabbit poly-
clonal antibody (1:5000, C3, Genetex), and anti-p80-Ku mouse 
monoclonal antibody (1/500, GE2.9.5, Millipore). Following 
incubation with the primary antibody, the membrane was washed 
3 times in PBS-Tween 0.05% and then incubated at room tem-
perature for 45 min in the presence of either HRP-conjugated 
goat anti-rabbit IgG antibody (1:10000, Enzo, Life Sciences) 
or HRP-conjugated goat anti-mouse IgG antibody (1:2000, 
Santa Cruz). Signals on the membrane were revealed using the 
SuperSignal West Pico Chemiluminescent Substrate (Pierce, 
Thermo Scientific), and after exposure to Fuji Medical X-RAY 
films (Fujifilm). Before applying a new antibody, the membrane 
was subjected to a 10 min incubation in 0.4 M NaOH at room 
temperature, three washes in PBS-Tween 0.05%, and incubation 
in a PBS solution containing 4% non-fat milk and 0.05% Tween 
20 during 1h at room temperature.
Slot Blot analysis of 5hmC
Genomic DNA was extracted using the SDS/Proteinase K 
lysis method as described previously.40 It was then treated with 
RNase A (1µg/µl final concentration) for 30 min, and puri-
fied by phenol/chloroform extractions and ethanol precipita-
tion. The Nanodrop ND-1000 spectrophotometer (Isogen, Life 
Sciences) was used for quantification. DNA samples were dena-
tured by incubation in a solution of 0.4 mM NaOH and 10 mM 
EDTA at 99 °C for 10 min, and then chilled on ice. Aliquots 
(500 ng for HEK293T and 2 µg for TERA-1) were slotted on 
positively charged nylon Hybond™ membranes (Amesham, 
GE Healthcare) using a Hybri.Slot 24 blotting apparatus (Core, 
Life Sciences). Membranes were thereafter washed quickly in 
2 x SSC, dried, and cross-linked by UV exposure. Blocking of 
the membranes was performed by incubation in PBS containing 
5% dry milk and 0.05% Tween, during 1h at room tempera-
ture. They were then probed with an anti-5hmC rabbit polyconal 
antibody (1:10000, #39769, Active Motif), during an overnight 
incubation at 4 °C. After three washes in PBS-Tween 0.05%, the 
membranes were incubated at room temperature for 45 min in 
the presence of HRP-conjugated goat anti-rabbit IgG antibody 
(1:10000, Enzo, Life Sciences). Signals on the membranes were 
revealed using the SuperSignal West Pico Chemiluminescent 
Substrate (Pierce, Thermo Scientific), and after exposure to 
Fuji Medical X-RAY films (Fujifilm). Membranes were there-
after washed quickly in PBS-Tween 0.05%, before staining in a 
methylene blue solution (0.02% methylene blue, 0.3M NaOH, 
pH 5.2). Films and stained membranes were scanned, and slot 
intensities were quantified using ImageJ.
Analysis of lung squamous cell carcinoma mRNA data sets
We used data sets from the TCGA (Nature 2012), which were 
obtained on Agilent microarrays.41 The gene expression value 
in each sample was reported to the mean value in all samples. 
Relative gene expression values were then log
2
 transformed for 
subsequent analyses. Samples were sorted according to their rela-
tive GABRA3 expression value. GABRA3low and GABRA3high sub-
groups were defined so as to match the proportion of GABRA3 
negative/positive (60% neg. and 40% pos.) samples determined 
by RT-qPCR experiments in NSCLC lung carcinomas, see 
Figure 1C). Two-tailed unpaired t test was used for statistical 
analyses.
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